The Impact of Transgenic IGF-IR Overexpression on Mammary Development and Tumorigenesis

Overview

Journal J Mammary Gland Biol Neoplasia

Date 2008 Nov 13

PMID 19002570

Citations 13

Authors

Robert A Jones

Roger A Moorehead

Affiliations

Soon will be listed here.

Abstract

Insulin-like growth factor-I and -II (IGF-I and IGF-II) and/or the type I insulin-like growth factor receptor (IGF-IR) have been implicated in a number of human tumors including breast cancer. However, despite being implicated in breast cancer for approximately 25 years and given that transgenic technology has been available for about the same period of time, it is surprising that transgenic mice overexpressing the IGF-IR in the mammary gland have only recently been characterized. This review will describe the effects of IGF-IR overexpression on mammary ductal morphogenesis and mammary tumorigenesis in the two available transgenic models.

Citing Articles

Transgenic overexpression of the miR-200b/200a/429 cluster inhibits mammary tumor initiation.

Watson K, Yi R, Moorehead R Transl Oncol. 2021; 14(12):101228.

PMID: 34562686 PMC: 8473771. DOI: 10.1016/j.tranon.2021.101228.

Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.

Gennari A, Foca F, Zamarchi R, Rocca A, Amadori D, De Censi A Breast Cancer Res Treat. 2020; 181(1):61-68.

PMID: 32200486 DOI: 10.1007/s10549-020-05596-4.

Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes.

Spiliotaki M, Mavroudis D, Kokotsaki M, Vetsika E, Stoupis I, Matikas A Mol Oncol. 2017; 12(1):21-32.

PMID: 28766847 PMC: 5748482. DOI: 10.1002/1878-0261.12114.

Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells.

Saleh S, Thompson D, McConkey J, Murray P, Moorehead R BMC Cancer. 2016; 16:359.

PMID: 27282619 PMC: 4901464. DOI: 10.1186/s12885-016-2396-9.

Crosstalk of the Insulin-Like Growth Factor Receptor with the Wnt Signaling Pathway in Breast Cancer.

Rota L, Wood T Front Endocrinol (Lausanne). 2015; 6:92.

PMID: 26106366 PMC: 4460810. DOI: 10.3389/fendo.2015.00092.

References

Bonnette S, Hadsell D . Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology. 2001; 142(11):4937-45. DOI: 10.1210/endo.142.11.8500. View

Boxer R, Jang J, Sintasath L, Chodosh L . Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004; 6(6):577-86. DOI: 10.1016/j.ccr.2004.10.013. View

Jones R, Campbell C, Wood G, Petrik J, Moorehead R . Reversibility and recurrence of IGF-IR-induced mammary tumors. Oncogene. 2009; 28(21):2152-62. DOI: 10.1038/onc.2009.79. View

Carboni J, Lee A, Hadsell D, Rowley B, Lee F, Bol D . Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 2005; 65(9):3781-7. DOI: 10.1158/0008-5472.CAN-04-4602. View

Muller W, Sinn E, Pattengale P, Wallace R, Leder P . Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988; 54(1):105-15. DOI: 10.1016/0092-8674(88)90184-5. View

Kim H, Litzenburger B, Cui X, Delgado D, Grabiner B, Lin X . Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol. 2007; 27(8):3165-75. PMC: 1899918. DOI: 10.1128/MCB.01315-06. View

Furstenberger G, Morant R, Senn H . Insulin-like growth factors and breast cancer. Onkologie. 2003; 26(3):290-4. DOI: 10.1159/000071627. View

Yanochko G, Eckhart W . Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res. 2006; 8(2):R18. PMC: 1557721. DOI: 10.1186/bcr1392. View

Wang T, Cardiff R, Zukerberg L, Lees E, Arnold A, SCHMIDT E . Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994; 369(6482):669-71. DOI: 10.1038/369669a0. View

10.

Jones R, Campbell C, Petrik J, Moorehead R . Characterization of a novel primary mammary tumor cell line reveals that cyclin D1 is regulated by the type I insulin-like growth factor receptor. Mol Cancer Res. 2008; 6(5):819-28. DOI: 10.1158/1541-7786.MCR-07-2157. View

11.

Hadsell D, Alexeenko T, Klimentidis Y, Klemintidis Y, Torres D, Lee A . Inability of overexpressed des(1-3)human insulin-like growth factor I (IGF-I) to inhibit forced mammary gland involution is associated with decreased expression of IGF signaling molecules. Endocrinology. 2001; 142(4):1479-88. DOI: 10.1210/endo.142.4.8087. View

12.

Pravtcheva D, Wise T . Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool. 1998; 281(1):43-57. View

13.

Jang J, Boxer R, Chodosh L . Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol. 2006; 26(21):8109-21. PMC: 1636749. DOI: 10.1128/MCB.00404-06. View

14.

LeRoith D, Neuenschwander S, Wood T, Hennighausen L . Insulin-like growth factor-I and insulin-like growth factor binding protein-3 inhibit involution of the mammary gland following lactation: studies in transgenic mice. Prog Growth Factor Res. 1995; 6(2-4):433-6. DOI: 10.1016/0955-2235(96)00009-9. View

15.

Resnik J, Reichart D, Huey K, Webster N, Seely B . Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 1998; 58(6):1159-64. View

16.

Burrin D, Fiorotto M, Hadsell D . Transgenic hypersecretion of des(1-3) human insulin-like growth factor I in mouse milk has limited effects on the gastrointestinal tract in suckling pups. J Nutr. 1999; 129(1):51-6. DOI: 10.1093/jn/129.1.51. View

17.

Hadsell D, Greenberg N, Fligger J, Baumrucker C, Rosen J . Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology. 1996; 137(1):321-30. DOI: 10.1210/endo.137.1.8536631. View

18.

Hadsell D, Murphy K, Bonnette S, Reece N, Laucirica R, Rosen J . Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene. 2000; 19(7):889-98. DOI: 10.1038/sj.onc.1203386. View

19.

Morali O, Delmas V, MOORE R, Jeanney C, Thiery J, Larue L . IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene. 2001; 20(36):4942-50. DOI: 10.1038/sj.onc.1204660. View

20.

Nielsen T, Andrews H, Cheang M, Kucab J, Hsu F, Ragaz J . Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res. 2004; 64(1):286-91. DOI: 10.1158/0008-5472.can-03-1242. View